🔍 Module 15 of 17 — Operations
FDA
Inspections
An FDA inspection is one of the highest-stakes events a regulated facility will face. What happens during those days determines whether the facility gets a clean bill of health, receives a list of observations, or triggers a Warning Letter cascade. This module covers the types of FDA inspections, what investigators look for, the Form 483 process, how to respond effectively, the three EIR classification outcomes, and how consultants can help before, during, and after.
FDA's Legal Inspection Authority
FDA's authority to inspect regulated facilities comes from 21 U.S.C. § 374 — Section 704 of the FD&C Act. This authority allows FDA investigators to enter and inspect any factory, warehouse, or establishment in which food, drugs, devices, or cosmetics are manufactured, processed, packed, or held — at reasonable times and within reasonable limits.
The "reasonable times" and "reasonable limits" language has been interpreted broadly by courts. FDA does not need a warrant to inspect a regulated facility. Refusing an FDA inspection is itself a violation of the FD&C Act under 21 U.S.C. § 331(f) — and refusing access tends to trigger the most serious enforcement responses FDA has available. Facilities should never refuse an inspection.
// The Inspection Authority Principle
You Cannot Refuse. But You Can Prepare.
FDA can inspect any registered facility. You cannot legally refuse. But the outcome of an inspection is not pre-determined — a well-prepared facility consistently achieves better inspection outcomes than an unprepared one, regardless of their underlying compliance status. Preparation means having clean, organized records; trained staff who know how to respond to investigator questions; and documented CAPA for any known gaps. Preparing for an inspection is not gaming the system — it IS the system working as intended.
Types of FDA Inspections
Routine
Surveillance Inspection
Scheduled based on FDA's risk-based inspection frequency schedule. Most facilities are inspected on a cycle — food facilities typically every 3–5 years, pharmaceutical facilities every 2–3 years for high-risk, less frequently for lower-risk. Surveillance inspections assess general cGMP compliance and product quality. These are the most common type of inspection.
Pre-Approval
PAI — Pre-Approval Inspection
Conducted before FDA approves a new NDA, ANDA, BLA, or NADA. Verifies that the manufacturing facility's actual operations match what was described in the application. A PAI failure — even for cGMP issues unrelated to the specific product — can delay approval by 12–24 months. All PAIs are unannounced for domestic facilities and scheduled (with notice) for foreign facilities.
For Cause
Compliance / For-Cause Inspection
Triggered by specific evidence of a problem: a Warning Letter, an import alert, a consumer complaint, an adverse event report, a recall, a whistleblower complaint, or a tip. For-cause inspections are the most intense and most consequential. The investigator arrives knowing what they're looking for and will focus on the identified issue — but a for-cause inspection typically expands to a full GMP review.
Food Safety
FSMA Inspection
Specific to food facilities under FSMA. Verifies that the facility has a written Food Safety Plan, that it was prepared by a PCQI, that preventive controls are implemented and monitored, and that records meet FSMA requirements. FSMA inspections assess the facility's entire food safety system, not just sanitation. The Food Safety Plan is the first document requested.
Importer
FSVP Inspection
Inspects U.S. importers for compliance with the Foreign Supplier Verification Program. FDA checks: is there a written FSVP for each foreign supplier? Is the hazard analysis complete? Are verification activities being conducted? Are records maintained? FSVP inspections happen at the U.S. importer's place of business — not at the foreign facility.
Post-483
Follow-Up Inspection
Conducted after a facility has received a Form 483 or Warning Letter, to verify that the corrective actions promised in the response were actually implemented. If promised corrections are not found — or if new violations are discovered — the follow-up inspection can trigger more serious enforcement action than the original inspection.
During an Inspection — What Investigators Do
Understanding the investigator's process helps facilities prepare appropriate responses without over-sharing or under-sharing. FDA investigators follow a defined inspection protocol but have significant discretion in how they conduct the inspection.
| Phase | What Happens | Facility Response |
|---|---|---|
| Arrival and Credentials | Investigator presents credentials (FDA badge) and FDA Form 482 (Notice of Inspection). The facility must acknowledge receipt — but does not need to sign anything at this point. | Alert the inspection team immediately. Have a designated escort assigned to accompany the investigator at all times. Contact your regulatory consultant or regulatory attorney if available. |
| Opening Meeting | Investigator explains the scope of the inspection, requests the facility's organizational chart, registered responsible official, and often the first records (e.g., batch records, CAPA log, complaint file). | Be cooperative, professional, and factual. Do not volunteer information about known problems — answer questions truthfully but precisely. Provide only what is requested. |
| Records Review | Investigator reviews SOPs, batch records, CAPA records, training records, deviation reports, OOS investigation records, complaint files, change control logs, and calibration/maintenance logs. This is where most observations originate. | Provide records promptly. Do not alter, hide, or delay production of records — doing so is a violation and often makes things significantly worse. If a record contains errors, explain the error factually. |
| Physical Walkthrough | Investigator tours the facility: manufacturing areas, laboratories, warehouses, utilities. Looks for cleanliness, equipment status, labeling of materials, pest evidence, temperature controls, personnel behavior, and overall GMP compliance. | Areas should be in normal working condition — not specially cleaned only for inspection. Personnel should behave as they normally would. Attempting to hide ongoing violations during a walkthrough typically makes things worse. |
| Sample Collection | Investigator may collect samples of finished products, in-process materials, or environmental swabs. Samples are collected under 21 U.S.C. § 374 — refusal is not permitted. The investigator will provide a receipt for samples collected. | Cooperate with sample collection. Keep copies of all sample receipts. Note the lot numbers of all sampled products so you can monitor what becomes of those lots. |
| Closeout Meeting | Investigator presents the Form 483 (if observations exist) and discusses each observation with facility management. This is the facility's first opportunity to clarify misunderstandings or provide information that might affect how observations are written. | Listen carefully to each observation. Provide factual clarifications where the investigator may have misunderstood something. Do not argue, become defensive, or promise corrections you cannot deliver. Request a copy of the 483 — you are entitled to it. |
Form 483 — Inspectional Observations
Form 483 (Inspectional Observations) is the written record of conditions observed during an inspection that the investigator believes may constitute violations of the FD&C Act. Receiving a Form 483 is not the same as receiving a Warning Letter — it is a list of observations that the facility has the opportunity to respond to before FDA decides on further action.
483
Form 483 Issued at Closeout
The investigator presents the Form 483 at the end of the inspection. Each observation is numbered and describes: what was observed, where it was observed, and which specific regulation it may violate. The facility is not required to sign the 483 — only to acknowledge receipt. The 483 is a public document once finalized — it will appear in FDA's database within 30 days.
15d
Written Response Within 15 Business Days
The facility should submit a written response to the 483 within 15 business days. While not legally required, a prompt, substantive response to a 483 is one of the most powerful tools a facility has. FDA reviewers specifically evaluate whether the 483 response demonstrates understanding of the problems, meaningful corrective actions, and realistic timelines. A poor or no response often leads directly to a Warning Letter.
EIR
Establishment Inspection Report Prepared by Investigator
After completing the inspection, the investigator prepares an Establishment Inspection Report (EIR) — a comprehensive narrative of everything that happened during the inspection. The EIR is reviewed by the investigator's supervisor and FDA's compliance office. It includes the 483 observations, the facility's verbal responses during the inspection, any samples collected, and the investigator's recommendation for further action. The EIR is released to the public under FOIA after enforcement action is resolved.
OAC
Official Action Indicated Classification — Warning Letter or Other Action
Based on the EIR and the 483 response, FDA's district compliance office classifies the inspection. If significant violations remain unresolved, FDA issues a Warning Letter. For serious or repeated violations, FDA may pursue injunctions, seizures, or criminal referrals. The Warning Letter is covered in detail in Module 16.
EIR Classification — The Three Possible Outcomes
NAI
No Action Indicated
No significant GMP violations found. No Form 483 issued (or only minor observations that were satisfactorily addressed). The inspection record is closed with no further action. NAI is the best possible outcome — it reflects a facility in genuine compliance. Facilities with consistent NAI outcomes get longer intervals between inspections.
VAI
Voluntary Action Indicated
Minor to moderate GMP violations found. Form 483 issued. FDA believes the facility can and will correct the violations voluntarily without formal enforcement action. The facility's 483 response is critical here — a strong, credible response with documented corrective actions often keeps a VAI from escalating to OAI. VAI facilities are re-inspected sooner than NAI facilities.
OAI
Official Action Indicated
Serious or repeated GMP violations that FDA believes require formal regulatory action. OAI triggers further enforcement: Warning Letters, import alerts, injunctions, seizures, or criminal referrals. A weak or non-responsive 483 response significantly increases the likelihood of OAI classification. OAI classification is public and is one of the most commercially damaging outcomes a pharmaceutical facility can receive.
How to Respond to a Form 483 Effectively
A well-written 483 response is one of the most important documents a regulated facility will ever produce. It can prevent a Warning Letter, demonstrate to FDA that the facility takes compliance seriously, and set the tone for the ongoing regulatory relationship. A poor response achieves the opposite.
✅ Elements of an Effective 483 Response
For each observation:
• Acknowledge the observation — do not minimize or dispute factual findings
• State the root cause: why did this happen?
• Describe corrective actions already taken (with evidence: updated SOPs, completed training records, corrected batch records)
• Describe preventive actions to prevent recurrence
• Provide a realistic timeline for anything not yet completed
• Attach documentary evidence for every completed correction
Overall tone: Cooperative, accountable, specific. FDA wants to see that you understand what went wrong and have a credible plan to prevent recurrence.
• Acknowledge the observation — do not minimize or dispute factual findings
• State the root cause: why did this happen?
• Describe corrective actions already taken (with evidence: updated SOPs, completed training records, corrected batch records)
• Describe preventive actions to prevent recurrence
• Provide a realistic timeline for anything not yet completed
• Attach documentary evidence for every completed correction
Overall tone: Cooperative, accountable, specific. FDA wants to see that you understand what went wrong and have a credible plan to prevent recurrence.
🚫 Common 483 Response Mistakes
• Disputing factual findings without compelling evidence — makes you look defensive
• Vague commitments: "We will improve our procedures" with no specifics
• Unrealistic timelines: "All corrections will be complete in 2 weeks" for systemic issues
• Missing evidence: claiming corrections were made but providing no documentation
• Promising more than you can deliver — FDA will follow up
• Late responses — submitting after 15 business days signals the facility doesn't take it seriously
• Not addressing all observations — FDA notices when observations are skipped
• Vague commitments: "We will improve our procedures" with no specifics
• Unrealistic timelines: "All corrections will be complete in 2 weeks" for systemic issues
• Missing evidence: claiming corrections were made but providing no documentation
• Promising more than you can deliver — FDA will follow up
• Late responses — submitting after 15 business days signals the facility doesn't take it seriously
• Not addressing all observations — FDA notices when observations are skipped
Top 10 Things Investigators Look For First
Experienced FDA investigators follow patterns. These are the records and areas investigators consistently prioritize — the ones most likely to reveal systemic quality problems quickly.
| Priority | What | Why It's First |
|---|---|---|
| #1 | CAPA System | The most revealing quality system indicator. A robust CAPA system with root cause analyses, timely completions, and effectiveness checks = mature quality culture. An empty or superficial CAPA log = systemic problems. Investigators ask to see CAPA records in the first 30 minutes of most pharmaceutical inspections. |
| #2 | Batch Records for Distributed Products | Pull recent batch records and look for incomplete entries, missing signatures, corrective entries, and OOS results. Batch records are the most direct evidence of what actually happened during production. |
| #3 | OOS / Laboratory Investigation Records | High OOS rates, invalidated OOS investigations without assignable cause, or test-fail-discard-retest patterns are major data integrity red flags. Investigators ask for OOS logs and review investigations for adequacy. |
| #4 | Consumer Complaint Files | Complaints reveal what products are failing in the real world. A low complaint rate may indicate a facility isn't capturing all complaints. Complaints not investigated, or without MDR analysis for devices, = immediate observation. |
| #5 | Electronic System Audit Trails | For facilities using LIMS, electronic batch records, or HPLC software, investigators specifically check whether audit trails are enabled and whether any data has been deleted or overwritten. Disabled audit trails = data integrity observation. |
| #6 | Change Control Log | Changes not documented in change control = GMP violation. Changes to critical processes not reported to FDA (for approved products) = regulatory violation. Investigators look for changes that occurred without documentation. |
| #7 | Incoming Component Testing Records | For supplement manufacturers especially: is identity testing being performed on incoming ingredients? Not just accepting the supplier's CoA? For drug manufacturers: are all raw materials tested against specifications before use? |
| #8 | Temperature and Storage Records | Temperature monitoring records for controlled storage areas. Products stored outside specified conditions = potential adulteration. Missing temperature records = data integrity concern and potential product quality issue. |
| #9 | Pest Control Records | For food and supplement facilities: pest control service records, trap logs, evidence of current pest control program. Any evidence of active pest infestation = immediate critical observation, potential for product recall. |
| #10 | Training Records vs. Actual Tasks | Are personnel performing tasks they've been trained to perform? Is training current (i.e., updated when SOPs are revised)? Personnel performing GMP tasks without documented training = GMP violation. |
✦ Module 15 — Key Takeaways
- FDA's inspection authority under 21 U.S.C. § 374 is broad and does not require a warrant. Refusing an inspection is a violation of the FD&C Act and triggers the most serious enforcement responses. Facilities should never refuse — but they should be well-prepared.
- Six types of inspections: surveillance (routine), pre-approval (PAI before NDA/ANDA approval), for-cause (triggered by specific evidence of a problem), FSMA (food safety), FSVP (importer supplier verification), and follow-up (verifying 483 corrections). Pre-approval and for-cause inspections carry the highest stakes.
- During an inspection, be cooperative, factual, and precise. Provide exactly what is requested — nothing more, nothing less. Accompany the investigator at all times. Never alter, hide, or delay production of records. Alert your regulatory consultant or attorney immediately upon receiving the Form 482 Notice of Inspection.
- Form 483 observations are not violations — they are the investigator's findings of conditions that may constitute violations. The facility has 15 business days to respond. A strong, specific, evidence-backed response with root causes, completed corrections, and realistic timelines can prevent the 483 from escalating to a Warning Letter.
- The EIR classification determines what happens next: NAI (no action — clean inspection), VAI (voluntary action — 483 corrections expected), or OAI (official action — Warning Letter or more serious enforcement). Strong 483 responses that demonstrate credible corrective actions significantly increase the likelihood of VAI over OAI classification.
- Investigators consistently prioritize: CAPA system, batch records, OOS investigations, complaint files, electronic audit trails, change control logs, incoming component testing, temperature records, pest control records, and training vs. task alignment. A facility prepared on these ten areas is prepared for most inspections.
Need inspection preparation or 483 response support?
Regovant provides mock FDA inspections, GMP readiness assessments, Form 483 response writing, and CAPA development for regulated manufacturers worldwide.